NASDAQ:XOMA
XOMA Corporation Stock News
$24.78
-0.660 (-2.59%)
At Close: May 03, 2024
XOMA Earns Milestone for First Patient Dosed in Phase 3 Development Program
07:30am, Monday, 03'rd May 2021
EMERYVILLE, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has earned a $0.5 million milestone from Janssen Biotech, Inc.
New Preferred Stock IPOs, April 2021
01:27pm, Tuesday, 27'th Apr 2021
New Preferred Stock IPOs, April 2021
XOMA's Royalty Portfolio Grows with Addition of Three Royalty Assets
09:05am, Thursday, 15'th Apr 2021
EMERYVILLE, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) today announced its portfolio of potential future milestone and royalty assets has increased with the addition of
XOMA Announces Closing of Depositary Shares Offering and Exercise of Underwriters' Option
07:30am, Monday, 12'th Apr 2021
Raised aggregate gross proceeds of $40 million
XOMA Prices $35 Million Offering of Depositary Shares
07:02pm, Tuesday, 06'th Apr 2021
Depositary shares represent an interest in 8.375% Series B Cumulative Perpetual Preferred Stock Depositary shares represent an interest in 8.375% Series B Cumulative Perpetual Preferred Stock
XOMA Announces Offering of Depositary Shares and Series B Cumulative Perpetual Preferred Stock
04:05pm, Monday, 05'th Apr 2021
EMERYVILLE, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has commenced an underwritten registered public offering of
Xoma (XOMA) Beats Q4 Earnings and Revenue Estimates
11:23am, Wednesday, 10'th Mar 2021
Xoma (XOMA) delivered earnings and revenue surprises of 2.33% and 126.07%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
XOMA Reports Fourth Quarter and Full-Year 2020 Financial Results and Operating Highlights
07:30am, Wednesday, 10'th Mar 2021
Recognized revenue of $29.4 million Six assets in the Company's milestone and royalty portfolio advanced to Phase 2 clinical development Completed $24.6 million Series A Perpetual Preferred Stock
Xoma (XOMA) to Report Q4 Results: Wall Street Expects Earnings Growth
01:38pm, Tuesday, 02'nd Mar 2021
Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
XOMA to Present at Upcoming Investor Conferences
04:05pm, Tuesday, 23'rd Feb 2021
EMERYVILLE, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present at the following upcoming investor conferences
XOMA: A Royalty Aggregator To Watch
04:43pm, Monday, 04'th Jan 2021
XOMA has built a large portfolio of drug royalties, over 65, with the potential to build a biotechnology business with high upside but limited and diversified downside protection. This royalty aggrega
XOMA to Present at H.C. Wainwright Virtual BioConnect 2021 and Biotech Showcase Digital Conferences
04:05pm, Monday, 04'th Jan 2021
EMERYVILLE, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present at two upcoming investor conferences:
XOMA Announces Exercise of Green Shoe Option and Closes Preferred Stock Offering
05:00pm, Monday, 21'st Dec 2020
EMERYVILLE, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced the closing of its previously announced underwritten registered
XOMA Prices $22 Million Offering of Series A Cumulative Perpetual Preferred Stock
06:22pm, Thursday, 10'th Dec 2020
EMERYVILLE, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced the pricing of its underwritten registered public offering of 88
XOMA Announces Offering of Series A Cumulative Perpetual Preferred Stock
07:52am, Thursday, 10'th Dec 2020
EMERYVILLE, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has commenced an underwritten registered public offering of s
